For example, it was postulated that interstitial lung disease caused by gefitinib, an EGFR inhibitor used in the treatment of EGFR-mutated non-squamous NSCLC, is most likely related to a decrease in alveolar regeneration, a process normally regulated by EGFR, in a population with a high co-incidence of lung disease [44]. Here, EGFR is linked to lung disorder.